ClickHouse Announces Strategic Collaboration Agreement with AWS to Advance Real-Time Data Analytics and Generative AI Innovation
ClickHouse, Inc., a leader in real-time analytics, announced today that it has signed a five-year strategic collaboration agreement (SCA) with Amazon Web Services (AWS), designed to accelerate innovation in real-time data warehousing, observability, business intelligence, machine learning, and generative AI solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210976702/en/
ClickHouse announces strategic collaboration agreement with AWS (Graphic: Business Wire)
The partnership will expand on ClickHouse’s relationship with AWS and introduce new integrations between ClickHouse Cloud and AWS services including Amazon Data Firehose, Amazon Relational Database Service (RDS), AWS Glue, and Amazon Bedrock. Together, this will make it easier for customers to build and manage high-performance analytics and generative AI applications. Additionally, this will provide customers with seamless deployment, enhanced interoperability, and optimal performance of data-intensive workloads powered by ClickHouse on AWS.
In addition to tighter integrations, ClickHouse and AWS will create new tailored industry solutions for customers ranging from finance to e-commerce to gaming. These solutions will enable organizations to harness the power of ClickHouse’s real-time analytics engine alongside AWS services to drive transformational outcomes. The two companies will also work on joint go-to-market activities to empower enterprises with advanced tools to extract actionable insights from their data at scale.
“The reliable infrastructure and global reach of AWS were crucial for the successful launch of ClickHouse Cloud,” said Aaron Katz, CEO of ClickHouse. “Our AWS Marketplace listing significantly expanded our customer reach, while the AWS Partner Network helped us engage with enterprise clients. This led to 150% incremental growth in our customer base on AWS Marketplace in 2024. Now with the strategic collaboration agreement, we strengthen focus on integrations, joint solutions and go-to-market activities to help customers unlock the full potential of their data and drive innovation in their respective industries.”
“We continue to invest in helping growth-stage companies, like ClickHouse, leverage AWS infrastructure, resources, and services like AWS Marketplace to rapidly grow and scale their businesses,” said Julia Chen, Vice President AWS Partner Core. “By integrating ClickHouse Cloud with AWS services such as Amazon Bedrock, customers can leverage the strength of both companies to more easily build advanced real-time applications, such as instant fraud detection, adaptive user experiences, and dynamic operational intelligence—unlocking new possibilities to stay ahead in today’s competitive landscape.”
Helping customers get the best business value from their data lake and data analytics investments is central to the collaboration between ClickHouse and AWS. Since launching ClickHouse Cloud on AWS in 2022, thousands of ClickHouse deployments have already been created, supporting joint customers ranging from startups to Fortune 500 companies. Every day, ClickHouse customers on AWS run over 2 billion queries scanning over 1.5 quadrillion records on top of 50 petabytes of data.
"By migrating our analytics workloads to ClickHouse Cloud on AWS we simplified the integration with data residing in AWS, achieved significant improvement in query performance, and project much lower annual costs. This has let us build new features faster that help our customers better understand their consumers and how their engagement strategies are performing," said Jon Hyman, Cofounder and Chief Technology Officer at Braze [NASDAQ: BRZE].
This collaboration underscores the value of ClickHouse and AWS to provide flexibility and unlock greater business value for customers across industries. For more information please visit: www.clickhouse.com
About ClickHouse
ClickHouse is a fast, open-source columnar database management system that allows for real-time data processing and analytics. Engineered for high performance, ClickHouse Cloud delivers exceptional query speed, making it an ideal solution for handling large volumes of data. Trusted by leading companies like Lyft, Deutsche Bank, and LangChain, ClickHouse Cloud enables businesses to gain critical insights and drive decision-making with its scalable, efficient, and robust data infrastructure. For more information, visit clickhouse.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210976702/en/
Contacts
Tyler Hannan
tyler@clickhouse.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces Approval of HYQVIA ® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia27.12.2024 08:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID)2. The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20). The administration of rHuPH20 increases the dispersion and absorption of immunoglobulin (IG) in the subcutaneous tissue, allowing larger volumes to be infu
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 16:00:00 EET | Press release
Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 100 points. TIME and Statista analyzed 3,000 major companies from 150 countries, focusing exclusively on those with trans
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 09:00:00 EET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 09:00:00 EET | Press release
ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors (corner cube prisms) designed to reflect laser beams directly back to their source, regardless of the an
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 09:00:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom